Gathering long-term data on safety and effectiveness

摘要

The COVID-19 pandemic is unique because it is the first time that so many vaccines are developed in such a short period of time. Moreover, it is one of the first times that mRNA vaccine technologies are widely implemented. This outburst of immunological research was inevitably accompanied by raised public awareness. Common interest sparked the need for a critical re-appraisement of vaccine effectiveness and safety. Preliminary results from Phase 3 clinical trials show a high degree of effectiveness, reaching up to 95% for some mRNA vaccines without serious side effects.